Table 1 General characteristics of included studies.
Author (years) | Participants (n) | Intervention | Dose | Age (years) | BMI (Kg/m2) | HbA1c (%) | Weight (kg) | Country | Duration |
|---|---|---|---|---|---|---|---|---|---|
Miyagawal21 2015 | 280 | Dulaglutide | 0.75 mg/week | 57.2 ± 9.6 | 25.6 ± 3.6 | 8.2 ± 0.8 | 71.3 ± 12.5 | Japan | 26 weeks |
137 | Liraglutide | 0.9 mg/day | 57.9 ± 10.4 | 25.5 ± 3.5 | 8.1 ± 0.9 | 70.2 ± 12.5 | |||
Chen22 2018 | 239 | Dulaglutide | 0.75 mg/week | 53.8 ± 10.1 | 26.2 ± 3.5 | 8.0 ± 1.0 | – | China, Korean, Taiwan | 26 weeks |
239 | Dulaglutide | 1.5 mg/week | 52.7 ± 10.8 | 25.8 ± 3.4 | 8.0 ± 1.0 | – | |||
242 | Glimepiride | 1–3 mg/day | 52.0 ± 10.1 | 25.7 ± 3.1 | 7.9 ± 1.0 | – | |||
Shi23 2020 | 186 | Dulaglutide | 0.75 mg/week | 53.8 ± 9.8 | 26.0 ± 3.3 | 8.0 ± 1.0 | 70.7 ± 12.0 | China | 26 weeks |
184 | Dulaglutide | 1.5 mg/week | 52.8 ± 10.4 | 25.5 ± 3.2 | 8.0 ± 1.0 | 69.7 ± 10.8 | |||
186 | Glimepiride | 1–3 mg/day | 52.7 ± 9.6 | 25.3 ± 2.9 | 7.9 ± 1.0 | 69.1 ± 10.6 | |||
Li24 2019 | 196 | Dulaglutide | 0.75 mg/week | 54.1 ± 10.0 | 26.2 ± 3.3 | 8.3 ± 1.1 | 73.2 ± 12.0 | China | 26 weeks and 52 weeks |
200 | Dulaglutide | 1.5 mg/week | 54.5 ± 10.0 | 25.8 ± 3.2 | 8.4 ± 1.2 | 71.9 ± 12.2 | |||
195 | Insulin Glargine | Once-daily | 55.0 ± 9.2 | 26.0 ± 3.2 | 8.3 ± 1.0 | 72.5 ± 12.5 | |||
Ghosal25 2018 | 30 | Dulaglutide | 1.5 mg/week | 48.2 ± 8.5 | 32.8 ± 5.6 | 8.3 ± 1.2 | 87.2 ± 11.8 | India | 13 weeks |
30 | Liraglutide | 1.2 mg/day | 47.3 ± 10.5 | 34.9 ± 4.7 | 8.5 ± 1.4 | 89.4 ± 14.2 |
